US Oncology, BioMarin Partner on Phase III BMN 673 Study

US Oncology Research is collaborating with BioMarin Pharmaceutical on a Phase III study to investigate the use of BMN 673, a PARP inhibitor, in metastatic breast cancer patients who test positive for BRCA1 or BRCA2 gene mutations. The study will investigate the effectiveness and safety of BMN 673. Thirteen U.S. Oncology Research affiliated practices with 56 locations will participate in the study.
 
The Phase III, open-label, randomized, parallel, 2-arm, multi-center study of BMN 673 versus physician’s choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer, who have received no more than two prior chemotherapy regimens for metastatic disease, will investigate the drug’s effectiveness, evaluate its safety, and compare it to commonly used treatments.